Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia

Overview

Journal Case Rep Hematol

Publisher Wiley

Specialty Hematology

Date 2016 Feb 24

PMID 26904322

Citations 2

Authors

Stephen E Langabeer

Karl Haslam

David OBrien

Johanna Kelly

Claire Andrews

Ciara Ryan

Richard Flavin

Patrick J Hayden

Christopher L Bacon

Affiliations

Soon will be listed here.

Abstract

The development of acute lymphoblastic leukemia in an existing myeloproliferative neoplasm is rare with historical cases unable to differentiate between concomitant malignancies or leukemic transformation. Molecular studies of coexisting JAK2 V617F-positive myeloproliferative neoplasms and mature B cell malignancies indicate distinct disease entities arising in myeloid and lymphoid committed hematopoietic progenitor cells, respectively. Mutations of CALR in essential thrombocythemia appear to be associated with a distinct phenotype and a lower risk of thrombosis yet their impact on disease progression is less well defined. The as yet undescribed scenario of pro-B cell acute lymphoblastic leukemia arising in CALR mutated essential thrombocythemia is presented. Intensive treatment for the leukemia allowed for expansion of the original CALR mutated clone. Whether CALR mutations in myeloproliferative neoplasms predispose to the acquisition of additional malignancies, particularly lymphoproliferative disorders, is not yet known.

Citing Articles

Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis.

Visani G, Etebari M, Fuligni F, DI Guardo A, Isidori A, Loscocco F Cancers (Basel). 2023; 15(6).

PMID: 36980671 PMC: 10046249. DOI: 10.3390/cancers15061785.

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.

Alhuraiji A, Naqvi K, Huh Y, Ho C, Verstovsek S, Bose P Clin Case Rep. 2018; 6(1):155-161.

PMID: 29375856 PMC: 5771935. DOI: 10.1002/ccr3.1264.

References

Braich T, Grogan T, Hicks M, Greenberg B . Terminal lymphoblastic transformation in polycythemia vera. Am J Med. 1986; 80(2):304-6. DOI: 10.1016/0002-9343(86)90029-x. View

Gangat N, Wolanskyj A, McClure R, Li C, Schwager S, Wu W . Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2006; 21(2):270-6. DOI: 10.1038/sj.leu.2404500. View

Barbui T . The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?. Semin Hematol. 2004; 41(2 Suppl 3):15-7. DOI: 10.1053/j.seminhematol.2004.02.006. View

Klampfl T, Gisslinger H, Harutyunyan A, Nivarthi H, Rumi E, Milosevic J . Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379-90. DOI: 10.1056/NEJMoa1311347. View

Langabeer S, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K . Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol. 2015; 95(4):270-9. DOI: 10.1111/ejh.12578. View

Pietra D, Rumi E, Ferretti V, Di Buduo C, Milanesi C, Cavalloni C . Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2015; 30(2):431-8. PMC: 4740452. DOI: 10.1038/leu.2015.277. View

Nagai Y, Kawahara M, Sugino N, Shimazu Y, Hishizawa M, Yamashita K . A case of minor BCR-ABL1 positive acute lymphoblastic leukemia following essential thrombocythemia and originating from a clone distinct from that harboring the JAK2-V617F mutation. Exp Hematol Oncol. 2014; 3(1):6. PMC: 3932988. DOI: 10.1186/2162-3619-3-6. View

Aitchison R, Black A, Greaves M . Polycythaemia rubra vera transforming to acute lymphoblastic leukaemia. Clin Lab Haematol. 1987; 9(2):201-4. DOI: 10.1111/j.1365-2257.1987.tb01402.x. View

Vannucchi A, Masala G, Antonioli E, Susini M, Guglielmelli P, Pieri L . Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev. 2009; 18(7):2068-73. DOI: 10.1158/1055-9965.EPI-09-0353. View

10.

Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, Fiacchini M . Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol. 2009; 84(4):215-20. DOI: 10.1002/ajh.21360. View

11.

Anastasi J, Pettenati M, Le Beau M, Kwaan H, Weil S . Acute lymphoblastic leukemia in a patient with longstanding polycythemia vera: cytogenetic analysis reveals two distinct abnormal clones. Am J Hematol. 1988; 29(1):33-7. DOI: 10.1002/ajh.2830290108. View

12.

Tefferi A, Wassie E, Lasho T, Finke C, Belachew A, Ketterling R . Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014; 28(12):2300-3. DOI: 10.1038/leu.2014.148. View

13.

Camos M, Cervantes F, Montoto S, Hernandez-Boluda J, Villamor N, Montserrat E . Acute lymphoid leukemia following polycythemia vera. Leuk Lymphoma. 1999; 32(3-4):395-8. DOI: 10.3109/10428199909167404. View

14.

Swierczek S, Nausova J, Jelinek J, Liu E, Roda P, Kucerova J . Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells. Am J Hematol. 2013; 88(2):157-8. PMC: 3556177. DOI: 10.1002/ajh.23362. View

15.

Murphy P, Sivakumaran M, van Rhee F, Watmore A, MITCHELL V . Acute lymphoblastic transformation of essential thrombocythaemia. Br J Haematol. 1995; 89(4):921-2. DOI: 10.1111/j.1365-2141.1995.tb08439.x. View

16.

Vannucchi A, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A . Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008; 22(7):1299-307. DOI: 10.1038/leu.2008.113. View

17.

Tao J, Zhang X, Lancet J, Bennett J, Cai L, Papenhausen P . Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation. Cancer Genet. 2014; 207(10-12):489-94. DOI: 10.1016/j.cancergen.2014.10.001. View

18.

Trifa A, Popp R, Cucuianu A, Banescu C, Tevet M, Martin B . CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients. Br J Haematol. 2014; 168(1):151-3. DOI: 10.1111/bjh.13076. View

19.

Litz C . Acute lymphoblastic leukemia in a case of essential thrombocythemia. Am J Clin Pathol. 1996; 106(2):206-8. DOI: 10.1093/ajcp/106.2.206. View

20.

Randi M, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F . Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica. 2005; 90(2):261-2. View